{"log_id": 6840842147271929341, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0, "average": 0.999147, "min": 0.999147}, "location": {"width": 24, "top": 251, "height": 23, "left": 240}, "words": "者"}, {"probability": {"variance": 0.001973, "average": 0.986286, "min": 0.725888}, "location": {"width": 627, "top": 287, "height": 38, "left": 303}, "words": "(2)静脉滴注135mg/m2,滴注时间大于24小时,并给予顺铂75mg/m"}, {"probability": {"variance": 0.007241, "average": 0.982683, "min": 0.494775}, "location": {"width": 685, "top": 331, "height": 33, "left": 279}, "words": "2.对于已经接受过化疗的卵巢癌患者,目前剂量和方案有几种,但最佳的剂"}, {"probability": {"variance": 0.000138, "average": 0.992402, "min": 0.954656}, "location": {"width": 724, "top": 372, "height": 34, "left": 239}, "words": "量方案还不清楚。推荐治疗方案为:静脉滴注135mg/m2或者175mg/m2,每3周"}, {"probability": {"variance": 4e-06, "average": 0.998474, "min": 0.992501}, "location": {"width": 247, "top": 415, "height": 25, "left": 238}, "words": "滴注1次,时间大于3小时"}, {"probability": {"variance": 0, "average": 0.999223, "min": 0.997457}, "location": {"width": 317, "top": 457, "height": 27, "left": 279}, "words": "对乳腺癌患者,推荐使用下列疗法"}, {"probability": {"variance": 1.3e-05, "average": 0.998013, "min": 0.986436}, "location": {"width": 680, "top": 498, "height": 29, "left": 279}, "words": "1对淋巴结阳性的乳腺癌的辅助治疗方案是:剂量为175mg/m2,静脉滴注"}, {"probability": {"variance": 0.01158, "average": 0.973957, "min": 0.396472}, "location": {"width": 723, "top": 537, "height": 32, "left": 239}, "words": "大于3小时,每3周1次,4个疗程,在含阿霉素的联合化疗后序贯使用临床"}, {"probability": {"variance": 1e-06, "average": 0.999062, "min": 0.996171}, "location": {"width": 441, "top": 580, "height": 26, "left": 236}, "words": "研究中用的是阿霉素联合环磷酰胺化疗4个疗程"}, {"probability": {"variance": 0.001764, "average": 0.990306, "min": 0.75558}, "location": {"width": 797, "top": 616, "height": 55, "left": 275}, "words": "2对初始化疗失败的转移性疾病或者辅助化疗6个月内出现复发的患者的有"}, {"probability": {"variance": 2.6e-05, "average": 0.997498, "min": 0.973891}, "location": {"width": 567, "top": 660, "height": 28, "left": 235}, "words": "效治疗方案为:175mg/m2,静脉超过3小时滴注,每3周1次"}, {"probability": {"variance": 3e-06, "average": 0.998357, "min": 0.993648}, "location": {"width": 299, "top": 702, "height": 27, "left": 275}, "words": "对非小细胞肺癌患者推荐方案为"}, {"probability": {"variance": 6.1e-05, "average": 0.996769, "min": 0.960301}, "location": {"width": 520, "top": 745, "height": 26, "left": 282}, "words": "75mg/m2,静脉滴注,滴注时间大于3小时。每3周1次"}, {"probability": {"variance": 1e-06, "average": 0.999285, "min": 0.995289}, "location": {"width": 445, "top": 784, "height": 29, "left": 275}, "words": "对艾滋病相关性卡波氏肉瘤,推荐的治疗方案为"}, {"probability": {"variance": 0.001956, "average": 0.984242, "min": 0.74688}, "location": {"width": 652, "top": 824, "height": 30, "left": 288}, "words": "35mg/m2,静脉滴注,滴注时间大于3小时,每3周1次或者100mg/m"}, {"probability": {"variance": 0.00391, "average": 0.983805, "min": 0.686493}, "location": {"width": 703, "top": 864, "height": 33, "left": 233}, "words": "静脉滴注,滴注时间大于3小时(剂量强度为45~50mg/m2week),每2周工次"}, {"probability": {"variance": 0.012457, "average": 0.957628, "min": 0.52138}, "location": {"width": 786, "top": 901, "height": 35, "left": 233}, "words": "在临床研究中,每3周1次静脉给予135mg/m2,滴注时间大于3小时的性比ARM"}, {"probability": {"variance": 0.016052, "average": 0.96014, "min": 0.441485}, "location": {"width": 777, "top": 924, "height": 61, "left": 230}, "words": "后者更大。另外,所有体能状态较差的患者,使用了后一方案(每两周静公杂"}, {"probability": {"variance": 0.001002, "average": 0.983539, "min": 0.875769}, "location": {"width": 304, "top": 989, "height": 26, "left": 239}, "words": "00mg/m2,滴注时间大于3小时)"}, {"probability": {"variance": 0.007468, "average": 0.947711, "min": 0.757213}, "location": {"width": 196, "top": 945, "height": 63, "left": 872}, "words": "医约有限公司"}, {"probability": {"variance": 0.003516, "average": 0.971872, "min": 0.765056}, "location": {"width": 748, "top": 1003, "height": 63, "left": 273}, "words": "鉴于进展期的HIV患者均有免疫抑制,对这些患者推荐使用改良方案"}, {"probability": {"variance": 0.000719, "average": 0.988128, "min": 0.881351}, "location": {"width": 685, "top": 1070, "height": 35, "left": 272}, "words": "1.减少三种预防用药中的地塞米松的剂量,用量为口服10mg(而不是20mg)"}, {"probability": {"variance": 0.00088, "average": 0.99053, "min": 0.827199}, "location": {"width": 684, "top": 1110, "height": 32, "left": 272}, "words": "2.只有当中性粒细胞计数至少为1000个/mm3时,才可首次或者再次使用本"}, {"probability": {"variance": 0, "average": 0.999707, "min": 0.999162}, "location": {"width": 66, "top": 1153, "height": 25, "left": 231}, "words": "品治疗"}, {"probability": {"variance": 0.002705, "average": 0.989434, "min": 0.681921}, "location": {"width": 684, "top": 1193, "height": 29, "left": 272}, "words": "3对严重中性粒细胞减少症(中性粒细胞小于500个/mm3持续一周或更长)"}, {"probability": {"variance": 0.000688, "average": 0.993118, "min": 0.873093}, "location": {"width": 446, "top": 1234, "height": 26, "left": 230}, "words": "的患者,在后面的疗程中紫杉醇的剂量减少20%"}, {"probability": {"variance": 0.000877, "average": 0.984833, "min": 0.918484}, "location": {"width": 220, "top": 1276, "height": 25, "left": 273}, "words": "4临床需要时使用GCS"}, {"probability": {"variance": 1e-05, "average": 0.998325, "min": 0.98638}, "location": {"width": 680, "top": 1317, "height": 29, "left": 273}, "words": "对实体瘤患者的治疗(卵巢、乳腺和非小细胞肺癌),只有当中性粒细胞至"}, {"probability": {"variance": 0.001136, "average": 0.986788, "min": 0.839926}, "location": {"width": 723, "top": 1357, "height": 31, "left": 230}, "words": "少为1500个/mm3,血小板至少为100,000个/mm3时,才可再次使用本品。对于"}, {"probability": {"variance": 0.004778, "average": 0.978844, "min": 0.589409}, "location": {"width": 724, "top": 1398, "height": 29, "left": 231}, "words": "基线或后续的中性粒细胞数低于1000个/m3的AIDS相关性卡波氏肉瘤患者不"}, {"probability": {"variance": 5.2e-05, "average": 0.996966, "min": 0.957336}, "location": {"width": 724, "top": 1439, "height": 30, "left": 228}, "words": "能使用本品。在本品治疗过程中出现了严重的中性粒细胞减少症(中性粒细胞小"}], "language": 3}